Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
Adult
Aged
Aged, 80 and over
Angiotensin Receptor Antagonists
/ pharmacology
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antihypertensive Agents
/ therapeutic use
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ immunology
Carcinoma, Non-Small-Cell Lung
/ complications
Drug Synergism
Female
Humans
Hypertension
/ complications
Japan
/ epidemiology
Lung Neoplasms
/ complications
Male
Middle Aged
Nivolumab
/ therapeutic use
Renin-Angiotensin System
/ drug effects
Retrospective Studies
Survival Analysis
Treatment Outcome
Renin–angiotensin system inhibitors
anti-programmed cell death 1/ligand-1 antibodies
immunotherapy
non-small cell lung cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
09
02
2021
revised:
18
02
2021
accepted:
19
02
2021
entrez:
4
4
2021
pubmed:
5
4
2021
medline:
10
4
2021
Statut:
ppublish
Résumé
The Renin-Angiotensin system (RAS) induces immunosuppression in the tumor microenvironment, and RAS inhibitors (RASi) improve the tumor immune microenvironment. We evaluated the impact of RASi on the efficacy anti-programmed cell death-1/Ligand-1 (anti-PD-1/PD-L1) antibodies. This retrospective study analyzed non-small cell lung cancer (NSCLC) patients who received anti-PD-1/PD-L1 antibodies monotherapy as second- or later-line treatment. We classified patients into those with or without use of RASi. A total of 256 NSCLC patients were included and 37 patients used RASi. The median PFS of patients treated with RASi was significantly longer than that of patients treated without (HR=0.59, 95%CI=0.40-0.88). The median OS of patients treated with RASi tended to be longer than that of patients treated without (HR=0.71, 95%CI=0.45-1.11). The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The Renin-Angiotensin system (RAS) induces immunosuppression in the tumor microenvironment, and RAS inhibitors (RASi) improve the tumor immune microenvironment. We evaluated the impact of RASi on the efficacy anti-programmed cell death-1/Ligand-1 (anti-PD-1/PD-L1) antibodies.
PATIENTS AND METHODS
METHODS
This retrospective study analyzed non-small cell lung cancer (NSCLC) patients who received anti-PD-1/PD-L1 antibodies monotherapy as second- or later-line treatment. We classified patients into those with or without use of RASi.
RESULTS
RESULTS
A total of 256 NSCLC patients were included and 37 patients used RASi. The median PFS of patients treated with RASi was significantly longer than that of patients treated without (HR=0.59, 95%CI=0.40-0.88). The median OS of patients treated with RASi tended to be longer than that of patients treated without (HR=0.71, 95%CI=0.45-1.11).
CONCLUSION
CONCLUSIONS
The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.
Identifiants
pubmed: 33813419
pii: 41/4/2093
doi: 10.21873/anticanres.14980
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Antibodies, Monoclonal, Humanized
0
Antihypertensive Agents
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
Nivolumab
31YO63LBSN
atezolizumab
52CMI0WC3Y
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2093-2100Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.